ChemConnection and Cristal Therapeutics Announce Successful GMP Production of CriPec® Docetaxel

ChemConnection and Cristal Therapeutics Announce Successful GMP Production of CriPec® Docetaxel
ChemConnection - Cristal Therapeutics - GMP Production - CriPec® Docetaxel - Chemelot Ventures

Oss and Maastricht, The Netherlands, June 1, 2016 / B3C newswire / — ChemConnection, a privately-held company manufacturing nanomedicines, bioconjugates, peptides, and small molecules, announces the successful GMP production of CriPec® docetaxel for its customer Cristal Therapeutics, a privately-held life sciences company developing nanomedicines against cancer and other diseases.

“ChemConnection has made a tremendous leap forward in becoming the global lead center for nanomedicines manufacturing” said Gerjan Kemperman, CEO of ChemConnection. “Recent investments in our manufacturing and analytical capabilities have boosted the advancement of nanomedicines. The successful completion of the process and analytical development, and GMP production of CriPec® docetaxel shows our expertise in sophisticated nanomedicine development and manufacturing. The continued partnership with Cristal Therapeutics will further strengthen our position in the nanomedicines manufacturing field.”

“We are very pleased with the partnership with ChemConnection on the scale up and GMP production of CriPec® docetaxel as being the lead product, based on our proprietary CriPec platform” said Joost Holthuis, CEO of Cristal Therapeutics. “The manufacturing of CriPec® docetaxel has resulted in a technical package that adds significant value to our portfolio and enabled the start of the clinical evaluation in patients with solid tumors.”

About ChemConnection ChemConnection BV is a contract manufacturing organization offering enabling technologies for the development and GMP manufacture of nanomedicines including drug loaded nanoparticles, liposomes, iron oxide nanoparticles, and theranostics. The offered technologies include continuous manufacturing technologies, purification technologies and analytical development and characterization technologies. The most advanced products currently in development are CriPec® docetaxel, a targeted drug loaded liposome, and an iron oxide nanoparticle for MRI diagnostics.

Contact
ChemConnection
Gerjan Kemperman
CEO Pivot Park
Alfred Nobel Building
Kloosterstraat 9, 5349 AB Oss The Netherlands
info@chemconnection.eu
+31 412 84 60 24

(this article first appeared on einnews.com)